Search

Displaying results 3161 - 3170 of 5900 in total
  1. Drug

    Blonanserin

    go.drugbank.com/drugs/DB09223
    Investigational

    As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  2. Drug

    Coagulation factor VIIa Recombinant Human

    go.drugbank.com/drugs/DB00036
    ApprovedInvestigational

    Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.

  3. Drug

    Udenafil

    go.drugbank.com/drugs/DB06267
    Approved

    Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena.

  4. Drug

    Bepridil

    go.drugbank.com/drugs/DB01244
    ApprovedWithdrawn

    It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).

  5. Drug

    Tiagabine

    go.drugbank.com/drugs/DB00906
    Approved

    Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.

  6. Drug

    Polyquaternium-10 (400 cps at 2%)

    go.drugbank.com/drugs/DB11356
    Approved

    It is commonly found in cosmetics and personal care products to mainly reduce static electricity and form films.

  7. Drug

    Iclepertin

    go.drugbank.com/drugs/DB19058
    Investigational

    Iclepertin is under investigation in clinical trial NCT05211947 (A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study).

  8. Drug

    Trioxsalen

    go.drugbank.com/drugs/DB04571
    ApprovedWithdrawn

    In research it can be conjugated to dyes for confocal microscopy and used to visualize sites of DNA damage.[3] The compound is has been explored for development of antisense oligonucleotides that can be … cross-linked specifically to a mutant mRNA sequence without affecting normal transcripts differing at even a single base pair.

  9. Drug

    PBI-1402

    go.drugbank.com/drugs/DB05480
    Experimental

    The compound activates neutrophils, enhancing their survival and activation with comparable efficacy to GM-CSF, G-CSF and EPO, which are currently used to treat anemia. … PBI-1402 appears to work on the PMN pathway, but its specific binding properties are not known. PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator.

  10. Drug

    Nadofaragene firadenovec

    go.drugbank.com/drugs/DB17381
    ApprovedInvestigational

    [L44381,L44431] BCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat. … Compared to [pembrolizumab], a smaller proportion of patients experienced grade 3-4 adverse events (4% vs 12.7%).[A255111]